Viking Therapeutics plans Ph2 trial for oral obesity drug after positive early-stage data

Viking Ther­a­peu­tics tout­ed ear­ly-stage obe­si­ty da­ta show­ing its oral GLP-1/GIP dual ag­o­nist pro­duced 5.3% weight loss and few side ef­fects, send­ing the com­pa­ny’s stock $VK­TX soar­ing about 23% on Tues­day morn­ing.

Viking’s once-dai­ly drug, dubbed VK2735, demon­strat­ed up to a 5.3% re­duc­tion in body weight from base­line in healthy pa­tients af­ter 28 days. Up to 57% of par­tic­i­pants who took VK2735 lost at least 5% of their body weight.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.